DOCSLIB.ORG

Metabotropic Glutamate Receptors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Metabotropic Glutamate Receptors mGluR Metabotropic glutamate receptors mGluR (metabotropic glutamate receptor) is a type of glutamate receptor that are active through an indirect metabotropic process. They are members of thegroup C family of G-protein-coupled receptors, or GPCRs. Like all glutamate receptors, mGluRs bind with glutamate, an amino acid that functions as an excitatoryneurotransmitter. The mGluRs perform a variety of functions in the central and peripheral nervous systems: mGluRs are involved in learning, memory, anxiety, and the perception of pain. mGluRs are found in pre- and postsynaptic neurons in synapses of the hippocampus, cerebellum, and the cerebral cortex, as well as other parts of the brain and in peripheral tissues. Eight different types of mGluRs, labeled mGluR1 to mGluR8, are divided into groups I, II, and III. Receptor types are grouped based on receptor structure and physiological activity. www.MedChemExpress.com 1 mGluR Inhibitors & Modulators (1R,2S)-VU0155041 (R)-ADX-47273 Cat. No.: HY-14417A Cat. No.: HY-13058B Bioactivity: (1R,2S)-VU0155041, Cis regioisomer of VU0155041, is a partial Bioactivity: (R)-ADX-47273 is a potent mGluR5 positive allosteric mGluR4 agonist with an EC of 2.35 μM. 50 modulator, with an EC50 of 168 nM for potentiation . Purity: 98.42% Purity: 99.25% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg 5 mg, 10 mg, 50 mg (RS)-MCPG (S)-MCPG (alpha-MCPG) Cat. No.: HY-100371 ((+)-MCPG) Cat. No.: HY-100406 Bioactivity: (RS)-MCPG is a non-selective group I/group II metabotropic Bioactivity: (S)-MCPG is the active isomer of (RS)-MCPG (Cat. No. glutamate receptor antagonist. HY-100371), non-selective group I/group II metabotropic glutamate receptor antagonist. In vivo: (S)-MCPG (20.8 μg) injected intraventricularly (i.c.v.) before testing impaired the performance of rats in the spatial version of the Morris… Purity: 98.0% Purity: 98.10% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg 5 mg, 10 mg, 25 mg, 50 mg ADX-47273 ADX88178 Cat. No.: HY-13058 Cat. No.: HY-18654 Bioactivity: ADX-47273 is a positive allosteric modulator selective for the Bioactivity: ADX88178 is a potent positive allosteric modulator for metabotropic glutamate receptor subtype mGluR5(EC50=170 nM). metabotropic glutamate receptor 4 ( mGluR4) with EC50 of IC50 value: 170 nM(EC50) [1] [2] Target: positive allosteric 4 nM for human mGluR4. modulator (PAM) of mGluR5 in vitro: ADX-47273 increased (9-fold) the response to threshold concentration of glutamate… Purity: 99.34% Purity: 98.59% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg 1 mg, 5 mg, 10 mg, 50 mg, 100 mg AZD 9272 AZD-8529 Cat. No.: HY-110254 Cat. No.: HY-107457 Bioactivity: AZD 9272 is a brain penetrant mGluR5 antagonist. Bioactivity: AZD-8529 is a potent, highly selective and orally bioavailable positive allosteric modulator of mGluR2, with an EC50 of 285 nM, and shows no positive allosteric modulator responses at 20-25 M on the mGluR1, 3, 4, 5, 6, 7, and 8 subtypes. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg Size: 250 mg, 500 mg Basimglurant BMT-145027 (RG7090; CTEP Derivative) Cat. No.: HY-15446 Cat. No.: HY-100728 Bioactivity: Basimglurant (RG7090) is a potent, selective and orally Bioactivity: BMT-145027 is an mGluR5 positive allosteric modulator available mGlu5 negative allosteric modulator with a Kd without inherent agonist activity, exhibits an EC50 of 47 of 1.1 nM. nM. Purity: 99.56% Purity: 98.0% Clinical Data: Phase 1 Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg 1 mg, 5 mg, 10 mg, 50 mg, 100 mg 2 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] CFMTI CPPHA Cat. No.: HY-100402 Cat. No.: HY-14612 Bioactivity: CFMTI is a potent and selective metabotropic glutamate Bioactivity: CPPHA is a selective positive allosteric modulator of mGluR5 receptor (mGluR) 1 allosteric antagonist with IC50 of 2.6 nM. receptor. The selectivity of CFMTI to mGluR1 over mGluR5 was >2000-fold. target : mGluR IC 50: 2.6 nM In vitro: The IC50 values of CFMTI against human mGluR5 were 5400 ± 1200 nM,… Purity: 98.0% Purity: 97.93% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg 5 mg, 10 mg, 50 mg CTEP DFMTI (RO 4956371; mGluR5 inhibitor) Cat. No.: HY-15445 (MK5435) Cat. No.: HY-100404 Bioactivity: CTEP (RO 4956371) is a novel, long-acting, orally bioavailable Bioactivity: DFMTI can completely block the rmGlu1 L757V glutamate allosteric antagonist of mGlu5 receptor response. with IC50 of 2.2 nM, and shows > 1000-fold selectivity over other mGlu receptors. Purity: 97.49% Purity: 99.25% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg 1 mg, 5 mg, 10 mg, 50 mg, 100 mg Dipraglurant E4CPG (ADX48621) Cat. No.: HY-14859 Cat. No.: HY-100372 Bioactivity: Dipraglurant (ADX 48621) is a mGluR5 antagonists with IC50 of Bioactivity: E4CPG is a novel group I/group II metabotropic glutamate 0.021 μM. receptor antagonist, more potent than (RS)-MCPG . Purity: 99.99% Purity: 98.0% Clinical Data: Phase 2 Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg 1 mg, 5 mg, 10 mg, 50 mg Eglumegad FITM (LY354740; Eglumetad) Cat. No.: HY-18941 Cat. No.: HY-101845 Bioactivity: Eglumegad (LY354740) is a highly potent and selective group Bioactivity: FITM is a negative allosteric modulator of mGlu1 receptor II (mGlu2/3) receptor agonist with IC50s of 5 and 24 nM on with a Ki of 2.5 nM. transfected human mGlu2 and mGlu3 receptors, respectively. Purity: 98.0% Purity: 98.82% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg Foliglurax monohydrochloride FPTQ (PXT002331 (monohydrochloride)) Cat. No.: HY-108703A Cat. No.: HY-100382 Bioactivity: Foliglurax monohydrochloride (PXT002331 monohydrochloride) is Bioactivity: FPTQ is mGluR1 antagonist with IC50 of 6 nM and 1.4 nM for a highly selective and potent, brain-penetrant mGluR4 human and mouse mGluR1 respectively. Inhibit [3H] FTIDC positive allosteric modulator (PAM), with an EC50 of 79±19 target: mGluR1 IC 50: 6 nM [1] In vivo: FPTQ exhibited dose-dependent and plasma concentration- dependent receptor nM [1]. Antiparkinsonian effect [1]. occupancy in the cerebellum and striatum. Compound A inhibit… Purity: 98.93% Purity: 99.89% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg 1 mg, 5 mg, 10 mg, 25 mg, 50 mg www.MedChemExpress.com 3 JNJ-40411813 JNJ-42153605 (ADX-71149) Cat. No.: HY-15748 Cat. No.: HY-18162 Bioactivity: JNJ-40411813 is a novel positive allosteric modulator of the Bioactivity: JNJ-42153605 is a positive allosteric modulator of the metabotropic Glutamate 2 receptor (mGlu2R) with EC50 of 147 metabotropic glutamate 2 ( mGlu2) receptor with an EC50 nM. IC50 value: 147 nM(EC50) Target: mGlu2R JNJ-40411813 of 17 nM. displayed an optimal interplay between potency, selectivity, favorable ADMET/PK and cardiovascular safety profile, and… Purity: 99.69% Purity: 98.10% Clinical Data: Phase 2 Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg 5 mg, 10 mg, 50 mg, 100 mg JNJ-46778212 JNJ16259685 (VU 0409551) Cat. No.: HY-19559 Cat. No.: HY-100407 Bioactivity: JNJ-46778212 (VU 0409551) is an mGlu5 positive allosteric Bioactivity: JNJ16259685 is a selective antagonist of mGlu1 receptor, modulator with an EC50 of 260 nM. and inhibits the synaptic activation of mGlu1 in a concentration-dependent manner with IC50 of 19 nM. Purity: 99.24% Purity: 98.85% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg 5 mg, 10 mg, 25 mg, 50 mg L-APB L-Cysteinesulfinic acid (L-AP 4) Cat. No.: HY-100781A Cat. No.: HY-100804 Bioactivity: L-APB is a potent and specific agonist for the group III Bioactivity: L-Cysteinesulfinic acid is a potent agonist at several rat metabotropic glutamate receptors ( mGluRs) with pEC s of mGluRs, with EC50s of 0.13, 0.29, 1.0, 249 μM for mGlu 50 3.92±0.03, 4.6±0.2, 3.9±0.2, 2.7±0.2, 4.0±0.2, and 3.94±0.08 4, mGlu 8, mGlu 6 and mGlu 7 receptors, respectively. for mGluR1, mGluR5, mGluR2, mGluR4, mGluR6, and mGluR8, respectively. Purity: 99.0% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 250 mg, 500 mg 1 mg, 5 mg L-Glutamine Lu AF21934 (L-Glutamic acid 5-amide) Cat.
Load more

Recommended publications
  • Mglur5 Modulation As a Treatment for Parkinson's Disease
    mGluR5 modulation as a treatment for Parkinson’s disease Kyle Farmer A thesis submitted to the Faculty of Graduate & Postdoctoral Affairs in partial fulfillment of requirements of the degree of Doctor of Philosophy in Neuroscience Carleton University Ottawa, ON Copyright © 2018 – Kyle Farmer ii Space Abstract Parkinson’s disease is an age related neurodegenerative disease. Current treatments do not reverse the degenerative course; rather they merely manage symptom severity. As such there is an urgent need to develop novel neuroprotective therapeutics. There is an additional need to stimulate and promote inherent neuro-recovery processes. Such processes could maximize the utilization of the existing dopamine neurons, and/or recruit alternate neuronal pathways to promote recovery. This thesis investigates the therapeutic potential of the mGluR5 negative allosteric modulator CTEP in a 6-hydroxydopamine mouse model of Parkinson’s disease. We found that CTEP caused a modest reduction in the parkinsonian phenotype after only 1 week of treatment. When administered for 12 weeks, CTEP was able to completely reverse any parkinsonian behaviours and resulted in full dopaminergic striatal terminal re-innervation. Furthermore, restoration of the striatal terminals resulted in normalization of hyperactive neurons in both the striatum and the motor cortex. The beneficial effects within the striatum iii were associated with an increase in activation of mTOR and p70s6K activity. Accordingly, the beneficial effects of CTEP can be blocked if co-administered with the mTOR complex 1 inhibitor, rapamycin. In contrast, CTEP had differential effects in the motor cortex, promoting ERK1/2 and CaMKIIα instead of mTOR. Together these data suggest that modulating mGluR5 with CTEP may have clinical significance in treating Parkinson’s disease.
    [Show full text]
  • Infiltrating Myeloid Cells Drive Osteosarcoma Progression Via GRM4 Regulation of IL23
    Published OnlineFirst September 16, 2019; DOI: 10.1158/2159-8290.CD-19-0154 RESEARCH BRIEF Infi ltrating Myeloid Cells Drive Osteosarcoma Progression via GRM4 Regulation of IL23 Maya Kansara 1 , 2 , Kristian Thomson 1 , Puiyi Pang 1 , Aurelie Dutour 3 , Lisa Mirabello 4 , Francine Acher5 , Jean-Philippe Pin 6 , Elizabeth G. Demicco 7 , Juming Yan 8 , Michele W.L. Teng 8 , Mark J. Smyth 9 , and David M. Thomas 1 , 2 ABSTRACT The glutamate metabotropic receptor 4 (GRM4 ) locus is linked to susceptibility to human osteosarcoma, through unknown mechanisms. We show that Grm4 − / − gene– targeted mice demonstrate accelerated radiation-induced tumor development to an extent comparable with Rb1 +/ − mice. GRM4 is expressed in myeloid cells, selectively regulating expression of IL23 and the related cytokine IL12. Osteosarcoma-conditioned media induce myeloid cell Il23 expression in a GRM4-dependent fashion, while suppressing the related cytokine Il12 . Both human and mouse osteosarcomas express an increased IL23:IL12 ratio, whereas higher IL23 expression is associated with worse survival in humans. Con- sistent with an oncogenic role, Il23−/− mice are strikingly resistant to osteosarcoma development. Agonists of GRM4 or a neutralizing antibody to IL23 suppressed osteosarcoma growth in mice. These fi ndings identify a novel, druggable myeloid suppressor pathway linking GRM4 to the proinfl ammatory IL23/IL12 axis. SIGNIFICANCE: Few novel systemic therapies targeting osteosarcoma have emerged in the last four decades. Using insights gained from a genome-wide association study and mouse modeling, we show that GRM4 plays a role in driving osteosarcoma via a non–cell-autonomous mechanism regulating IL23, opening new avenues for therapeutic intervention.
    [Show full text]
  • Metabotropic Glutamate Receptors
    mGluR Metabotropic glutamate receptors mGluR (metabotropic glutamate receptor) is a type of glutamate receptor that are active through an indirect metabotropic process. They are members of thegroup C family of G-protein-coupled receptors, or GPCRs. Like all glutamate receptors, mGluRs bind with glutamate, an amino acid that functions as an excitatoryneurotransmitter. The mGluRs perform a variety of functions in the central and peripheral nervous systems: mGluRs are involved in learning, memory, anxiety, and the perception of pain. mGluRs are found in pre- and postsynaptic neurons in synapses of the hippocampus, cerebellum, and the cerebral cortex, as well as other parts of the brain and in peripheral tissues. Eight different types of mGluRs, labeled mGluR1 to mGluR8, are divided into groups I, II, and III. Receptor types are grouped based on receptor structure and physiological activity. www.MedChemExpress.com 1 mGluR Agonists, Antagonists, Inhibitors, Modulators & Activators (-)-Camphoric acid (1R,2S)-VU0155041 Cat. No.: HY-122808 Cat. No.: HY-14417A (-)-Camphoric acid is the less active enantiomer (1R,2S)-VU0155041, Cis regioisomer of VU0155041, is of Camphoric acid. Camphoric acid stimulates a partial mGluR4 agonist with an EC50 of 2.35 osteoblast differentiation and induces μM. glutamate receptor expression. Camphoric acid also significantly induced the activation of NF-κB and AP-1. Purity: ≥98.0% Purity: ≥98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg (2R,4R)-APDC (R)-ADX-47273 Cat. No.: HY-102091 Cat. No.: HY-13058B (2R,4R)-APDC is a selective group II metabotropic (R)-ADX-47273 is a potent mGluR5 positive glutamate receptors (mGluRs) agonist.
    [Show full text]
  • Mglur5 Activity Moderates Vulnerability to Chronic Social Stress
    Neuropsychopharmacology (2015) 40, 1222–1233 & 2015 American College of Neuropsychopharmacology. All rights reserved 0893-133X/15 www.neuropsychopharmacology.org Homer1/mGluR5 Activity Moderates Vulnerability to Chronic Social Stress 1 1 1 1 1 Klaus V Wagner , Jakob Hartmann , Christiana Labermaier , Alexander S Ha¨usl , Gengjing Zhao , 1 1 2 1 1 1 Daniela Harbich , Bianca Schmid , Xiao-Dong Wang , Sara Santarelli , Christine Kohl , Nils C Gassen , 3,4 1 1 1 5 Natalie Matosin , Marcel Schieven , Christian Webhofer , Christoph W Turck , Lothar Lindemann , 6 5 1 1 ,1 Georg Jaschke , Joseph G Wettstein , Theo Rein , Marianne B Mu¨ller and Mathias V Schmidt* 1 2 Department of Stress Neurobiology and Neurogenetics, Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurobiology, Key Laboratory of Medical Neurobiology of Ministry of Health of China, Zhejiang Province Key Laboratory of Neurobiology, Zhejiang University 3 School of Medicine, Hangzhou, China; Faculty of Science, Medicine and Health and Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, NSW, Australia; 4Schizophrenia Research Institute, Sydney NSW, Australia; 5Roche Pharmaceutical Research and Early Development, Neuroscience, Ophthalmology, and Rare Diseases Translational Area (NORD), Basel, Switzerland; 6Roche Pharmaceutical Research and Early Development, Discovery Chemistry, Basel, Switzerland Stress-induced psychiatric disorders, such as depression, have recently been linked to changes in glutamate transmission in the central nervous system. Glutamate signaling is mediated by a range of receptors, including metabotropic glutamate receptors (mGluRs). In particular, mGluR subtype 5 (mGluR5) is highly implicated in stress-induced psychopathology. The major scaffold protein Homer1 critically interacts with mGluR5 and has also been linked to several psychopathologies.
    [Show full text]
  • Aβ Oligomers Induce Sex-Selective Differences in Mglur5 Pharmacology and Pathophysiological Signaling in Alzheimer Mice
    bioRxiv preprint doi: https://doi.org/10.1101/803262; this version posted June 10, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. TITLE: Aβ oligomers induce sex-selective differences in mGluR5 pharmacology and pathophysiological signaling in Alzheimer mice Khaled S. Abd-Elrahman1,2,6,#, Awatif Albaker1,2,7,#, Jessica M. de Souza1,2,8, Fabiola M. Ribeiro8, Michael G. Schlossmacher1,2,3,5, Mario Tiberi1,2,4,5, Alison Hamilton1,2,$ and Stephen S. G. Ferguson1,2,$,* 1University of Ottawa Brain and Mind Institute, 2Departments of Cellular and Molecular Medicine, 3 Medicine, 4Psychiatry, and the 5Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, K1H 8M5, Canada. 6Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt. 7Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, 12371, Saudi Arabia 8Department of Biochemistry and Immunology, ICB, Universidade Federalde Minas Gerais, Belo Horizonte, Brazil. #These authors contributed equally $ Co-senior authors ONE-SENTENCE SUMMARY: Aβ/PrPC complex binds to mGluR5 and activates its pathological signaling in male, but not female brain and therefore, mGluR5 does not contribute to the pathology in female Alzheimer’s mice. *Corresponding author Dr. Stephen S. G. Ferguson Department of Cellular and Molecular Medicine, University of Ottawa, 451 Smyth Dr. Ottawa, Ontario, Canada, K1H 8M5. Tel: (613) 562 5800 Ext 8889. [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/803262; this version posted June 10, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • Glutamatergic Regulation of Cognition and Functional Brain Connectivity: Insights from Pharmacological, Genetic and Translational Schizophrenia Research
    Title: Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research Authors: Dr Maria R Dauvermann (1,2) , Dr Graham Lee (2) , Dr Neil Dawson (3) Affiliations: 1. School of Psychology, National University of Ireland, Galway, Galway, Ireland 2. McGovern Institute for Brain Research, Massachusetts Institute of Technology, 77 Massachusetts Ave, Cambridge, MA, 02139, USA 3. Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, LA1 4YQ, UK Abstract The pharmacological modulation of glutamatergic neurotransmission to improve cognitive function has been a focus of intensive research, particularly in relation to the cognitive deficits seen in schizophrenia. Despite this effort there has been little success in the clinical use of glutamatergic compounds as procognitive drugs. Here we review a selection of the drugs used to modulate glutamatergic signalling and how they impact on cognitive function in rodents and humans. We highlight how glutamatergic dysfunction, and NMDA receptor hypofunction in particular, is a key mechanism contributing to the cognitive deficits observed in schizophrenia, and outline some of the glutamatergic targets that have been tested as putative procognitive targets for the disorder. Using translational research in this area as a leading exemplar, namely models of NMDA receptor hypofunction, we discuss how the study of functional brain network connectivity can provide new insight
    [Show full text]
  • Biomolecules
    biomolecules Review Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease Fabio Del Bello , Mario Giannella, Gianfabio Giorgioni * , Alessandro Piergentili and Wilma Quaglia Scuola di Scienze del Farmaco e dei Prodotti della Salute, Università di Camerino, Via S. Agostino 1, 62032 Camerino, Italy; [email protected] (F.D.B.); [email protected] (M.G.); [email protected] (A.P.); [email protected] (W.Q.) * Correspondence: [email protected]; Tel.: +39-0737402368 Received: 18 March 2019; Accepted: 6 April 2019; Published: 9 April 2019 Abstract: Levodopa (LD) is the most effective drug in the treatment of Parkinson’s disease (PD). However, although it represents the “gold standard” of PD therapy, LD can cause side effects, including gastrointestinal and cardiovascular symptoms as well as transient elevated liver enzyme levels. Moreover, LD therapy leads to LD-induced dyskinesia (LID), a disabling motor complication that represents a major challenge for the clinical neurologist. Due to the many limitations associated with LD therapeutic use, other dopaminergic and non-dopaminergic drugs are being developed to optimize the treatment response. This review focuses on recent investigations about non-dopaminergic central nervous system (CNS) receptor ligands that have been identified to have therapeutic potential for the treatment of motor and non-motor symptoms of PD. In a different way, such agents may contribute to extending LD response and/or ameliorate LD-induced side effects. Keywords: Parkinson’s disease; levodopa therapy; levodopa-induced side effects; dopaminergic drugs; non-dopaminergic receptor ligands 1. Introduction Parkinson’s disease (PD), also known as idiopathic paralysis agitans, is one of the most frequent chronic neurodegenerative diseases worldwide.
    [Show full text]
  • Development of Allosteric Modulators of Gpcrs for Treatment of CNS Disorders Hilary Highfield Nickols A, P
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Neurobiology of Disease 61 (2014) 55–71 Contents lists available at ScienceDirect Neurobiology of Disease journal homepage: www.elsevier.com/locate/ynbdi Review Development of allosteric modulators of GPCRs for treatment of CNS disorders Hilary Highfield Nickols a, P. Jeffrey Conn b,⁎ a Division of Neuropathology, Department of Pathology, Microbiology and Immunology, Vanderbilt University, USA b Department of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA article info abstract Article history: The discovery of allosteric modulators of G protein-coupled receptors (GPCRs) provides a promising new strategy Received 25 July 2013 with potential for developing novel treatments for a variety of central nervous system (CNS) disorders. Tradition- Revised 13 September 2013 al drug discovery efforts targeting GPCRs have focused on developing ligands for orthosteric sites which bind en- Accepted 17 September 2013 dogenous ligands. Allosteric modulators target a site separate from the orthosteric site to modulate receptor Available online 27 September 2013 function. These allosteric agents can either potentiate (positive allosteric modulator, PAM) or inhibit (negative allosteric modulator, NAM) the receptor response and often provide much greater subtype selectivity than Keywords: Allosteric modulator orthosteric ligands for the same receptors. Experimental evidence has revealed more nuanced pharmacological CNS modes of action of allosteric modulators, with some PAMs showing allosteric agonism in combination with pos- Drug discovery itive allosteric modulation in response to endogenous ligand (ago-potentiators) as well as “bitopic” ligands that GPCR interact with both the allosteric and orthosteric sites. Drugs targeting the allosteric site allow for increased drug Metabotropic glutamate receptor selectivity and potentially decreased adverse side effects.
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • World Journal of Pharmaceutical Research Nazir Et Al
    World Journal of Pharmaceutical Research Nazir et al . World Journal of Pharmaceutical SJIF ResearchImpact Factor 6.805 Volume 2, Issue 3, 731-739. Review Article ISSN 2277– 7105 AMINO ACID GLUTAMIC ACID ITS ANTICANCER PROPERTIES AND PHARMACOLOGY (A REVIEW) 1*Nazir Ahmad Wani and 2Mukhtar Ahmad Wani 1*Govt. Degree College Boys Anantnag Jammu & Kashmir (India). 2Department of Chemistry, IGNOU New Delhi (India). ABSTRACT Article Received on 20 Feb. 2013, Glutamine is a derivative of glutamic acid and is formed in the body Revised on 10 March. 2013, from glutamic acid and ammonia in an energy requiring reaction Accepted on 30 March. 2013 DOI: 10.20959/wjpr20133-7924 catalyzed by glutamine synthase. It also possesses anticancer activity. So the transportation and metabolism of glutamine are also discussed for better understanding the role of glutamic acid. Glutamates are the *Corresponding Author Nazir Ahmad Wani carboxylate anions and salts of glutamic acid. Here the roles of various Govt. Degree College Boys enzymes required for the metabolism of glutamates are also discussed. Anantnag Jammu & Kashmir (India). KEYWORDS: anticancer activity, glutamine synthase, glutamic acid. [email protected] INTRODUCTION Glutamate is a key compound in cellular metabolism. In humans, dietary proteins are broken down by digestion into amino acids, which serve as metabolic fuel for other functional roles in the body. A key process in amino acid degradation is transamination, in which the amino group of an amino acid is transferred to an α-ketoacid, typically catalysed by a transaminase.[1-4] Glutamine plays very important roles in tumor cell. Firstly it acts as a nitrogen donor in the nucleotide and amino acid biosynthesis, secondly glutamine helps in the uptake of essential amino acid and it maintains the activation of TOR kinase (Wise and Thompson, 2010).
    [Show full text]
  • GPCR/G Protein
    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com GPCR/G Protein G Protein Coupled Receptors (GPCRs) perceive many extracellular signals and transduce them to heterotrimeric G proteins, which further transduce these signals intracellular to appropriate downstream effectors and thereby play an important role in various signaling pathways. G proteins are specialized proteins with the ability to bind the nucleotides guanosine triphosphate (GTP) and guanosine diphosphate (GDP). In unstimulated cells, the state of G alpha is defined by its interaction with GDP, G beta-gamma, and a GPCR. Upon receptor stimulation by a ligand, G alpha dissociates from the receptor and G beta-gamma, and GTP is exchanged for the bound GDP, which leads to G alpha activation. G alpha then goes on to activate other molecules in the cell. These effects include activating the MAPK and PI3K pathways, as well as inhibition of the Na+/H+ exchanger in the plasma membrane, and the lowering of intracellular Ca2+ levels. Most human GPCRs can be grouped into five main families named; Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, and Secretin, forming the GRAFS classification system. A series of studies showed that aberrant GPCR Signaling including those for GPCR-PCa, PSGR2, CaSR, GPR30, and GPR39 are associated with tumorigenesis or metastasis, thus interfering with these receptors and their downstream targets might provide an opportunity for the development of new strategies for cancer diagnosis, prevention and treatment. At present, modulators of GPCRs form a key area for the pharmaceutical industry, representing approximately 27% of all FDA-approved drugs. References: [1] Moreira IS. Biochim Biophys Acta. 2014 Jan;1840(1):16-33.
    [Show full text]
  • Diamandis Thesis
    !"!#$ CHEMICAL GENETIC INTERROGATION OF NEURAL STEM CELLS: PHENOTYPE AND FUNCTION OF NEUROTRANSMITTER PATHWAYS IN NORMAL AND BRAIN TUMOUR INITIATING NEURAL PRECUSOR CELLS by Phedias Diamandis A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy. Department of Molecular Genetics University of Toronto © Copyright by Phedias Diamandis 2010 Phenotype and Function of Neurotransmitter Pathways in Normal and Brain Tumor Initiating Neural Precursor Cells Phedias Diamandis Doctor of Philosophy Department of Molecular Genetics University of Toronto 2010 &'(!)&*!% The identification of self-renewing and multipotent neural stem cells (NSCs) in the mammalian brain brings promise for the treatment of neurological diseases and has yielded new insight into brain cancer. The complete repertoire of signaling pathways that governs these cells however remains largely uncharacterized. This thesis describes how chemical genetic approaches can be used to probe and better define the operational circuitry of the NSC. I describe the development of a small molecule chemical genetic screen of NSCs that uncovered an unappreciated precursor role of a number of neurotransmitter pathways commonly thought to operate primarily in the mature central nervous system (CNS). Given the similarities between stem cells and cancer, I then translated this knowledge to demonstrate that these neurotransmitter regulatory effects are also conserved within cultures of cancer stem cells. I then provide experimental and epidemiologically support for this hypothesis and suggest that neurotransmitter signals may also regulate the expansion of precursor cells that drive tumor growth in the brain. Specifically, I first evaluate the effects of neurochemicals in mouse models of brain tumors. I then outline a retrospective meta-analysis of brain tumor incidence rates in psychiatric patients presumed to be chronically taking neuromodulators similar to those identified in the initial screen.
    [Show full text]